JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 August 2008

J Clin Pathol. Published Online First: 12 May 2008. doi:10.1136/jcp.2007.053892
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
jcp.2007.053892v1
61/8/934    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nunes, C. B
Right arrow Articles by Gobbi, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nunes, C. B
Right arrow Articles by Gobbi, H.

Histopathology

Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas

Cristiana B Nunes 1*, Rafael Malagoli Rocha 1, Jorge S Reis-Filho 2, Maryou Lambros 2, Gislene F S Rocha 1, Fernanda S F Sanches 1, Flavio N Oliveira 1 and Helenice Gobbi 1

1 Federal University of Minas Gerais, Brazil
2 The Breakthrough Breast Cancer Research Centre, United Kingdom

* To whom correspondence should be addressed. E-mail: cristianabnunes{at}gmail.com.

Accepted 4 April 2008


*   Abstract

Aims: We compared the ¡¥sensitivity¡¦ and ¡¥specificity¡¦ of new rabbit monoclonal antibody SP3 with those of mouse monoclonal and rabbit polyclonal antibodies to detect HER2 amplification as defined by chromogenic in situ hybridization (CISH). Methods and Results: Serial sections from tissue microarrays (TMAs) containing 84 breast carcinomas were submitted to CISH (Zymed HER2 Spot-Light"¥ kit) and immunohistochemistry, using NeoMarkers SP3 (rabbit monoclonal), DAKO A0485 and DAKO HercepTest (polyclonal), Novocastra NCL-CB11, Cell Marque CM-CB11, and Genentech 4D5 (mouse monoclonal). The best antibody concordance was between SP3 and HercepTest (kappa=0.74). SP3, A0485 and HercepTest detected all HER2 amplified tumours, but were less ¡¥specific¡¦ than mouse monoclonal antibodies. There were 3/38 (7.9%) and 8/38 (21.0%) of non-amplified tumours scored as 3+ using SP3 and A0485, respectively. 3/46 (6.5%) of amplified tumours were negative for NCL-CB11. SP3, HercepTest and A0485 showed no gene amplification on 55%, 62.5% and 92.3% of the 2+ scored tumours, but most of the 2+ scored tumours using monoclonal antibodies were amplified by CISH (80% to 92.3%). Conclusions: SP3 is more ¡¥sensitive¡¦ than mouse monoclonal antibodies for Her2 assessment. However, HercepTest, CB11 and 4D5 show higher ¡¥specificity¡¦ than SP3 for the identification of HER2 gene amplification. Mouse monoclonal antibodies show less Her2 2+ tumours and most of them are amplified by CISH. Word-count: 212







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.